Novartis AG has agreed to sell its 70.68% controlling stake in Novartis India Limited to a consortium led by ChrysCapital, with participation from existing minority investors and other strategic participants. The all-cash transaction values the stake at approximately ₹1,446 crore and marks Novartis AG’s complete exit from its listed Indian entity, allowing the company to focus on core innovative medicines while ChrysCapital aims to reposition Novartis India as a diversified generics and specialty pharma player.
Glimpse:
The deal involves ChrysCapital and co-investors acquiring Novartis AG’s entire 70.68% equity stake in Novartis India at ₹825 per share, representing a 25% premium to the 30-day VWAP and a 20% premium to the closing price before the announcement. Post-transaction, Novartis India will continue as a listed public company with the new promoters holding majority control. Novartis AG will retain its innovative portfolio rights in India through separate licensing and supply agreements, while the ChrysCapital-led group plans to strengthen the generics business, expand the portfolio, and drive operational efficiencies.
Global pharmaceutical major Novartis AG has entered into a definitive share purchase agreement to divest its entire 70.68% equity stake in its Indian listed subsidiary, Novartis India Limited, to a consortium led by ChrysCapital, one of India’s largest and most active private equity firms. The transaction, announced on February 26, 2026, is valued at approximately ₹1,446 crore at an agreed price of ₹825 per share.
The deal represents a clean exit for Novartis AG from its legacy Indian operations, allowing the Swiss company to sharpen its global focus on innovative medicines while transferring the mature generics and established brands business to a local investor group with deep experience in Indian pharma. The ChrysCapital-led consortium includes participation from certain existing minority shareholders and other strategic investors who will collectively hold the majority post-acquisition.
Novartis India Limited, listed on the BSE and NSE, currently markets a portfolio of generics, over-the-counter products, and certain established brands (including Voltaren, Onbrez, and Certican) in the Indian market. The company has a strong distribution network, manufacturing partnerships, and a well-recognized brand presence in chronic and acute therapy areas. Following the transaction, Novartis AG will continue to supply select innovative products to India under long-term licensing and supply agreements, ensuring continuity for patients on Novartis originator medicines.
ChrysCapital, which has a long history of successful investments in Indian healthcare and pharmaceuticals (including past exits from Mankind Pharma, Suven Life Sciences, and others), sees significant value-creation potential in Novartis India. The firm plans to invest further in expanding the generics portfolio, strengthening manufacturing and distribution capabilities, entering high-growth therapy areas (such as biosimilars and specialty generics), and leveraging digital tools to enhance reach in tier-2 and tier-3 markets.
The transaction is subject to customary regulatory approvals from the Competition Commission of India (CCI), stock exchanges, shareholders, and other relevant authorities, with closure expected in the second half of 2026. Upon completion, Novartis India will continue to operate as a listed public company with the new promoter group holding a controlling stake.
The divestment aligns with Novartis AG’s global strategy of actively managing its portfolio to focus on high-innovation, high-growth therapeutic areas while allowing mature businesses to be scaled by local operators with deep market knowledge. For ChrysCapital, the acquisition adds another marquee asset to its healthcare portfolio and reinforces its position as a leading investor in India’s pharmaceutical and life sciences sector.
Industry analysts view the deal as a positive development for Novartis India, which has faced margin pressures in the generics segment and will now benefit from focused local management and additional capital infusion. The transaction also reflects the continued attractiveness of India’s pharma market to private equity, particularly for established brands with strong distribution networks.
“This transaction marks a new chapter for Novartis India under strong Indian ownership. ChrysCapital’s deep healthcare expertise and long-term investment approach will help unlock the company’s full potential in one of the world’s most dynamic pharmaceutical markets.”
By
HB Team
